Treatment will consist of KD will consist of 3:1 [fat]: [protein + carbohydrate] weight ratio, with 1600 kcal restriction for patients with body mass index (BMI) of ≥ 21. The diet will be initiated with a 24 hour fast to induce ketosis. The diet will be supplemented with vitamins, calcium and phosphorus supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard. If seizure frequency does not improve after 3 months of KD treatment, [fat]: [protein + carbohydrate] weight ratio will be increased to 4:1

Epilepsy

KD will consist of 3:1 [fat]: [protein + carbohydrate] weight ratio, with 1600 kcal restriction

ketogenic diet

MidAtlantic Epilepsy and Sleep Center

Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy

Evaluation of the Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy: a Pilot Study.

Seizure frequency, adverse events and treatment compliance will be reviewed. The diet will be reviewed with the subject by the nutritionist before treatment initiation. Seizure frequency will be counted using a daily seizure diary. Subject's neurological and other clinical progress since the last visit will be reviewed. Concurrent medications will be documented. Vital signs and weight will be obtained, and a complete physical and neurological examination will be performed. Body mass index will be calculated. Subjects seizure/urine ketone diary will be reviewed at each visit.
Treatment compliance will be evaluated with urine ketone levels using the diaries and with serum b-hydroxy-butyrate (b-OH-butyrate, BOH) levels.

Adverse events and treatment compliance will be reviewed.Subject's neurological and other clinical progress since the last visit will be reviewed.

Quality of life will be evaluated with a standardized questionnaire of quality of life in patients with epilepsy, QOLIE-31-P.

Alertness will be evaluated with Epworth Sleepiness Scale.

Pavel Klein

Mid-Atlantic Epilepsy and Sleep Center, LLC

All study participants progressed from intravenous phenytoin alone to intravenous phenytoin plus probenecid

All Study Participants

Sex: Female, Male

Region of Enrollment

Intravenous Phenytoin Alone

Intravenous Phenytoin Plus Probenecid

Quantitative EEG Recordings

All study participants progressed from receiving intravenous phenytoin alone to intravenous phenytoin plus probenecid.

Dr. Jim McAuley

intravenous phenytoin (15 mg/kg) single dose

phenytoin

intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose

phenytoin and probenecid

The Ohio State University

Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy

Evaluating Transporter Protein Inhibitors in Patients With Epilepsy

Jim McAuley

Associate Professor

Obesity

Diabetes Mellitus, Type 2

Diabetes Mellitus, Adult-Onset

topiramate

A Study of the Efficacy and Safety of Topiramate in Obese Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy

A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy

uric acid/seizures

Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy

Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy

A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne